[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"insulin-sensitivity\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:insulin-sensitivity":37},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,27,0,25,[9,73,100,128,151,177,201,227,253,282,306,330,357,380,402,431,454,473,499,529,556,586,605,634,654],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":46,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":72},"100526751","effect-of-endoscopic-sleeve-gastroplasty-in-patients-with-obesity-and-mash-a-randomized-controlled-trial-100526751",false,"NCT06138821","Effect of Endoscopic Sleeve Gastroplasty in Patients With Obesity and MASH: A Randomized Controlled Trial","Effect of Endoscopic Sleeve Gastroplasty on Patients With Obesity and Concomitant Metabolic Dysfunction-Associated Steatohepatitis (MASH): A Multicenter, Open-label, Randomized Controlled Trial","Inclusion Criteria:\n\n1. Age ≥ 18 (male or female)\n2. BMI ≥30 kg\u002Fm2 or ≥27 kg\u002Fm2 with at least one obesity-related comorbidity\n3. Self-reported stable weight (no weight change \\>5%) for 6 months prior to the first study visit\n4. Willingness to follow protocol requirements, including signed informed consent, routine follow-up schedule, completing laboratory\u002Fimaging\u002Fadditional tests, and completing diet counseling\n5. Willingness to NOT start a new anti-obesity medication for the following 12 months\n6. Residing within a reasonable distance from the investigator's office and able to travel to the investigator to complete routine follow-up visits\n7. Ability to give informed consent\n8. Women of childbearing potential (i.e., not post-menopausal, nor surgically sterilized) must agree to use adequate birth control methods\n\nExclusion Criteria:\n\n1. Known history of other chronic liver diseases (viral hepatitis, autoimmune hepatitis, drug-induced hepatitis, and genetic)\n2. Treatment with vitamin E (at doses ≥800 IU\u002Fday), pioglitazone, obeticholic acid, or resmetirom \\\u003C90 days before the first study visit\n3. History of foregut or gastrointestinal (GI) surgery (except uncomplicated fundoplication, cholecystectomy or appendectomy)\n4. Prior bariatric surgery\n5. Prior endoscopic sleeve gastroplasty\n6. Any inflammatory disease of the GI tract, including severe (LA Grade C or D) esophagitis, Barrett's esophagus with dysplasia, gastric ulceration, duodenal ulceration, cancer or specific inflammation such as Crohn's disease\n7. Potential upper gastrointestinal bleeding conditions such as esophageal or gastric varices, congenital or acquired intestinal telangiectasis, or other congenital anomalies of the gastrointestinal tract such as atresias or stenoses\n8. Severe gastroesophageal reflux disease (GERD)\n9. A structural abnormality in the esophagus or pharynx, such as a stricture or diverticulum, that could impede passage of the endoscope.\n10. Achalasia or any other severe esophageal motility disorder\n11. Chronic abdominal pain\n12. Gastroparesis or intractable constipation\n13. Hepatic insufficiency or cirrhosis\n14. Severe coagulopathy\n15. Insulin-dependent diabetes (either type 1 or type 2) or a significant likelihood of requiring insulin treatment in the following 12 months or HgbA1C ≥ 12%\n16. Patients on an anti-platelet agent, anticoagulant agent or chronic\u002Froutine use of NSAIDs\n17. Patients on corticosteroids, immunosuppressants, or narcotics\n18. Patients on an anti-seizure or anti-arrhythmic medication\n19. Patients who are pregnant or breastfeeding\n20. Excessive alcohol consumption (\\>20 g per day for women; \\>30 g per day for men)\n21. Active smoking\n22. History of poorly controlled hypertension, coronary artery disease, congestive heart failure, cardiac arrhythmia\n23. History of respiratory diseases such as chronic obstructive pulmonary disease (COPD) requiring steroids, pneumonia, or cancer\n24. History of autoimmune connective tissue disorder such as lupus, scleroderma or immunocompromised disease\n25. History of active malignancy\n26. History of genetic or hormonal causes for obesity, such as Prader Willi syndrome\n27. History of endocrine disorders affecting weight, such as uncontrolled hypothyroidism\n28. Eating disorders, including night eating syndrome, bulimia, binge eating disorder or compulsive overeating\n29. Active psychological issues preventing participation in a lifestyle modification program as determined by a psychologist","ALL","18 Years",{"count":20,"type":21},132,"ESTIMATED","INTERVENTIONAL",[24],"NA","Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease globally. While weight loss through lifestyle modification is the standard treatment, most patients regain weight limiting ultimate improvement in liver disease. On the other end of the spectrum, bariatric surgery has shown promise in the treatment of MASLD\u002Fmetabolic dysfunction-associated steatohepatitis (MASH) due to its efficacy in inducing weight loss. Nevertheless, its adoption has been hindered by the perceived invasiveness of surgery.\n\nOver the past decade, endoscopic sleeve gastroplasty (ESG) has gained recognition as a promising minimally-invasive approach to weight loss. The procedure involves utilizing a Food and Drug Administration (FDA)-authorized endoscopic suturing device to reduce the gastric volume by 70%. Studies reveal that ESG is associated with approximately 18.2% weight loss at one year after the procedure, with sustained results for at least 10 years. Nevertheless, the effect of ESG on MASH remains unknown.\n\nIn this study, the investigators will compare ESG + lifestyle modification versus lifestyle modification alone in treating histologic MASH. The study will randomize patients to one of two different treatment options: ESG + lifestyle modification or lifestyle modification alone.",[27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45],"Obesity","Liver Diseases","Liver Fibrosis","Liver Fat","Metabolic Dysfunction-Associated Steatotic Liver Disease","Metabolic Dysfunction-Associated Steatohepatitis","MASLD","MASH","Weight Loss","Insulin Resistance","Insulin Sensitivity","Insulin Sensitivity\u002FResistance","Metabolic Disease","Diabetes","Diabetes Mellitus, Type 2","NASH With Fibrosis","Non-Alcoholic Fatty Liver Disease","Non Alcoholic Fatty Liver","Non-alcoholic Steatohepatitis",[47,48,49,50,51,52,53,54,55,56,57,58,59],"Gut Hormones","Endoscopic Bariatric and Metabolic Therapy (EBMT)","Intragastric Balloon (IGB)","Endoscopic Suturing","Endoscopic Sleeve Gastroplasty (ESG)","Weight Management","Endoscopic Gastric Remodeling (EGR)","Endoscopic Bariatric Therapy (EBT)","Fatty Liver","Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)","Metabolic Dysfunction-Associated Steatohepatitis (MASH)","Non-Alcoholic Fatty Liver Disease (NAFLD)","Non-Alcoholic Steatohepatitis (NASH)","RECRUITING","2026-06-23",{"date":63,"type":64},"2026-06-25","ACTUAL",{"date":66,"type":64},"2025-06-24",{"date":68,"type":21},"2028-06",{"name":70,"class":71},"Pichamol Jirapinyo, MD, MPH","OTHER",2,{"id":74,"slug":75,"hasResults":12,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":12,"sex":17,"minAge":81,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":22,"phases":85,"briefSummary":86,"conditions":87,"keywords":4,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":4},"100637708","improving-sleep-health-and-circadian-timing-to-support-cardiometabolic-health-in-adolescents-100637708","NCT07618117","Improving Sleep Health and Circadian Timing to Support Cardiometabolic Health in Adolescents","Mitigating Cardiometabolic Risk by Improving Sleep Health and Circadian Timing in Adolescents With Overweight\u002FObesity","REST","Inclusion Criteria:\n\n1. High school students between 14-19 years\n2. Overweight\u002Fobesity (BMI \\>85% for age and sex)\n3. Have habitually insufficient sleep, defined as ≤ 7 hours per night on school days\n4. Habitually inactive (≤ 3 h of physical activity reported per week)\n5. Tanner stage 4 or 5, based on breast development for girls and testicular size for boys.\n\nExclusion Criteria:\n\n1. Reported diagnosis of sleep disorder (e.g., insomnia, obstructive sleep apnea)\n2. Medical comorbidities that impact sleep or insulin sensitivity (e.g., diabetes \\[based on history or screening HbA1c\\])\n3. Regular use of medications affecting sleep or insulin sensitivity (e.g., stimulants, sleep aids, systemic steroids, insulin sensitizers, GLP-1 agonists)\n4. IQ\\\u003C70 or severe mental illness that may impact sleep or study participation (e.g., schizophrenia), eating disorder, or active suicidal ideation\n5. Schedules that would preclude participants from adhering to the sleep schedules (e.g., night-shift employment)","14 Years","19 Years",{"count":84,"type":21},60,[24],"Many teenagers get too little and late timed sleep. High body weight and diabetes are increasing in teenagers as well. This study plans to learn more about whether improving sleep habits can help improve how the body regulates blood sugar and energy use in teenagers who have higher body weight. To answer this question, the investigators plan to enroll teenagers who get \\\u003C7 hours of sleep on school nights and measure changes in blood sugars and energy use after two weeks of typical sleep (sleeping on their normal school schedule) and two weeks of a sleep intervention that includes spending longer time in bed at night, melatonin, and morning light.",[88,89,37],"Overweight Adolescents","Sleep","NOT_YET_RECRUITING","2026-05-26",{"date":93,"type":64},"2026-06-01",{"date":95,"type":21},"2026-08-25",{"date":97,"type":21},"2030-08-30",{"name":99,"class":71},"University of Colorado, Denver",{"id":101,"slug":102,"hasResults":12,"nctId":103,"briefTitle":104,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":106,"sex":17,"minAge":18,"maxAge":107,"enrollmentInfo":108,"targetDuration":4,"studyType":22,"phases":110,"briefSummary":111,"conditions":112,"keywords":115,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":127},"100526005","effect-of-weight-loss-on-intermuscular-adipose-tissue-imat-signaling-100526005","NCT06129110","Effect of Weight Loss on Intermuscular Adipose Tissue (IMAT) Signaling","Inclusion Criteria:\n\n* Generally healthy men and women aged 18-70\n* BMI between 30-40\n* Less than 1 hour of exercise per week\n* Women:\n\n  1. may be pre or post menopausal\n\nExclusion Criteria:\n\n* Type 1 or Type 2 diabetes\n* Thyroid disease\n* History of lung disease\n* Active use of nicotine\n* Severe plasma lipid disorders\n* Taking hormone replacement drugs, blood thinners, or thiazoladinediones\n* Women:\n\n  1. Currently going through menopause or peri-menopause\n  2. Pregnant or breastfeeding\n  3. History of Polycystic Ovary Syndrome",true,"70 Years",{"count":109,"type":21},70,[24],"The goal of this intervention study is to learn about how weight loss impacts molecular signaling of intermuscular adipose tissue (IMAT) in individuals with obesity. The main question it aims to answer is how inflammatory molecules secreted by IMAT promote muscle insulin resistance and inflammation, and how these same molecules are diminished after weight loss. Following screening visits involving body composition measures, blood testing, strength testing, and a thigh muscle biopsy, participants will go through a 12-week dietary intervention for weight loss. After 12 weeks, this will be followed by the same testing and biopsies that were completed before the intervention. Researchers will then compare outcomes of individuals who lost weight to individuals who did not lose weight.",[27,37,113,114,36],"Muscle Weakness","Adiposity",[116,117,35,118],"IMAT","Intermuscular Adipose Tissue","Diet","2026-05-13",{"date":121,"type":64},"2026-05-15",{"date":123,"type":64},"2024-01-31",{"date":125,"type":21},"2028-09-01",{"name":99,"class":71},1,{"id":129,"slug":130,"hasResults":12,"nctId":131,"briefTitle":132,"officialTitle":132,"acronym":133,"eligibilityCriteria":134,"healthyVolunteers":106,"sex":17,"minAge":18,"maxAge":135,"enrollmentInfo":136,"targetDuration":4,"studyType":22,"phases":138,"briefSummary":139,"conditions":140,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":127},"100501249","metabolic-adaptations-to-weight-loss-with-and-without-exercise-100501249","NCT05806801","Metabolic Adaptations to Weight Loss With and Without Exercise","WAX","Inclusion criteria\n\n* Age: 18-40\n* Body Mass Index: 30-40 kg\u002Fm2\n* Weight stable (±3kg for greater than or equal to about 2 months)\n* No regularly planned exercise\u002Fphysical activity\n* Women must have regularly occurring menses and must be premenopausal\n\nExclusion criteria\n\n* EKG abnormalities\n* Evidence\u002Fhistory of cardiovascular disease, diabetes or other metabolic disease\n* Medications known to affect lipid or glucose metabolism\n* Pregnant or lactating\n* Tobacco or e-cigarette use\n* Prior experience of hypersensitivity to insulin, human albumin, and potassium chloride injection.\n* Allergies\u002Fhypersensitivity to local anesthetics of the amide type (e.g., lidocaine)\n* History of hyperkalemia or potential for developing hyperkalemia (including but not limited to taking drugs that may induce hyperkalemia such as cardiac glycosides or potassium sparing diuretics)\n* Anti-coagulant medication (e.g., Coumadin, Rivaroxaban) and Lidocaine allergy\u002Fsensitivity are exclusion criteria for the biopsy procedure.","40 Years",{"count":137,"type":21},68,[24],"Study Purpose:\n\nThe combination of caloric restriction and exercise is the most common first-line treatment for obesity-related disorders, yet we know very little about how these two very different treatments work together. A deeper understanding about mechanisms underlying the health benefits of adding exercise to a weight loss program will not only aid efforts to optimize more effective lifestyle interventions, but it can also uncover novel targets for the treatment\u002Fprevention of obesity-related diseases.\n\nAlthough a reduction in body fat is the fundamental adaptation to weight loss, we know almost nothing about the effects that adding exercise has on structural and functional changes within fat tissue that may further enhance metabolic health. This is very important because many obesity-related metabolic health complications are tightly linked with abnormalities in abdominal fat tissue. We argue exercise-induced modifications in abdominal fat tissue will reveal persistent health benefits even if some weight is regained\n\nStudy Summary:\n\n10% Weight Loss Phase - Subject participation in the study will involve a series of metabolic tests before, at midpoint, and after undergoing a 10% weight loss program (with or without exercise training depending on group randomization). During this, subjects will be randomized into one of two different experimental groups:\n\n1. Moderate Intensity Continuous Training (MICT) exercise group\n2. No exercise (control) group\n\nFollow-up Phase: After completing the metabolic testing post-weight loss, all study-related diet and exercise supervision will end and subjects will be free to make their own choices regarding diet and exercise\u002Fphysical activity behavior. Subjects will then be asked to complete follow-up testing at 2-, 4- and 6- months post-weight loss.\n\nTotal involvement in the study for each subject will likely be about 10-13 months (4-7 months during weight loss phase, 6 months during follow-up phase).",[27,39,141,37,36,35],"Metabolic Syndrome","2026-04-10",{"date":144,"type":64},"2026-04-14",{"date":146,"type":64},"2023-07-19",{"date":148,"type":21},"2028-05-31",{"name":150,"class":71},"University of Michigan",{"id":152,"slug":153,"hasResults":12,"nctId":154,"briefTitle":155,"officialTitle":155,"acronym":4,"eligibilityCriteria":156,"healthyVolunteers":106,"sex":17,"minAge":18,"maxAge":157,"enrollmentInfo":158,"targetDuration":4,"studyType":22,"phases":160,"briefSummary":161,"conditions":162,"keywords":163,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":127},"100628786","the-importance-of-insulin-action-in-the-brain-for-the-immune-system-during-physical-activity-overweight-100628786","NCT07466173","The Importance of Insulin Action in the Brain for the Immune System During Physical Activity-Overweight","Inclusion Criteria:\n\n* BMI \\> 28 kg\u002Fm2\n* no known primary disease\n* hormonal contraception with a single-phase preparation\n\nExclusion Criteria:\n\n* alcohol or drug abuse\n* At screening: Hb \\\u003C 12 g\u002Fdl for women and Hb \\\u003C 14 g\u002Fdl for men\n* Any (clinical) condition that would endanger participant's safety or question scientific success according to a physician's opinion.","30 Years",{"count":159,"type":21},8,[24],"The goal of this clinical trial is to clarify the interaction of central insulin action and physical activity with the immune system. Therefore, participants will undergo bicycle spiroergometer tests. This approach will be compared between days with insulin delivery to the brain as nasal spray and days with placebo spray. In another trial (NCT06552130) lean participants already have been tested. Significant effects on circulating cytokines could be identified. In this amendment, overweight persons in which brain insulin resistance is expected will be tested.",[37],[164,165,166,167],"brain insulin action","autonomic nervous system","physical activity","immune system","2026-03-11",{"date":170,"type":64},"2026-03-16",{"date":172,"type":21},"2026-04",{"date":174,"type":21},"2027-06",{"name":176,"class":71},"University of Ulm",{"id":178,"slug":179,"hasResults":12,"nctId":180,"briefTitle":181,"officialTitle":182,"acronym":4,"eligibilityCriteria":183,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":107,"enrollmentInfo":184,"targetDuration":4,"studyType":22,"phases":186,"briefSummary":188,"conditions":189,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":192,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":127},"100591625","phase-1-a-study-to-evaluate-the-effect-of-retatrutide-on-insulin-secretion-and-insulin-sensitivity-in-adult-participants-with-type-2-diabetes-mellitus-100591625","NCT06982859","A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus","A Phase 1, Investigator- and Participant-Blinded Study to Evaluate the Effect of Retatrutide on α- and β- Cell Function and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus","Inclusion Criteria:\n\n* Have been diagnosed with Type 2 Diabetes Mellitus (T2DM) for at least 6 months prior to screening.\n* Treated with diet and exercise and metformin daily, with or without other allowed oral antihyperglycaemia medications (OAMs), 3 months prior to screening. Allowed OAMs are dipeptidyl peptidase-4 inhibitors (DPP-IV) inhibitors, sodium\u002Fglucose cotransporter 2 (SGLT2) inhibitors, glinides, and sulfonylureas.\n* Have a HbA1c value at screening of:\n\n  * 6.5% and ≤ 9.5 % if on metformin with or without SGLT2 inhibitors, or\n  * 6% and ≤8.5% if on metformin in combination with allowed OAMs that require washout.\n* Have venous access sufficient to allow for blood sampling as per the protocol.\n* Have clinical laboratory test results within normal reference range for the population or investigative site or results with acceptable deviations that are judged to be not clinically significant by the investigator.\n* Have a body mass index (BMI) between 25 kilograms per meter squared (kg\u002Fm²) and 45 kg\u002Fm², both inclusive, at screening.\n* Have had a stable body weight that is less than 5% change during the 3-month period prior to screening.\n\nExclusion Criteria:\n\n* Have Type 1 Diabetes Mellitus (T1DM)\n* Have had more than 1 episode of severe hypoglycaemia, as defined by the American Diabetes Association criteria, within 6 months before screening or a history of hypoglycaemia unawareness or poor recognition of hypoglycaemic symptoms; any participant that cannot communicate an understanding of hypoglycaemic symptoms and the appropriate treatment of hypoglycaemia prior to the first dose of study drug should also be excluded.\n* Have had 1 or more episodes of ketoacidosis or hyperosmolar state\u002Fcoma requiring hospitalisation within the 6 months prior to screening.\n* Are currently receiving, planning to receive, or in need of treatment, that is, intravitreal injections of Vascular Endothelial Growth Factor inhibitor or corticosteroids, focal\u002Fgrid macular laser surgery, panretinal photocoagulation, or vitrectomy for diabetic retinopathy at screening.\n* Have impaired renal estimated glomerular filtration rate \\\u003C60.0 mL\u002Fmin\u002F1.73 m² calculated by Chronic Kidney Disease-Epidemiology (2021).\n* Have acute or chronic pancreatitis or a history of acute idiopathic pancreatitis.\n* Have elevations in:\n\n  * serum aspartate aminotransferase (AST) \\>2.5X the upper limit of normal (ULN)\n  * serum alanine aminotransferase (ALT) \\>2.5X ULN\n  * total bilirubin level (TBL) \\>1.5X ULN (except, participants with Gilbert's syndrome), or\n  * Alkaline phosphatase (ALP) level ≥1.5X ULN\n* Show evidence of possible chronic or active hepatitis B, including hepatitis B core antibody and\u002For hepatitis B surface antigen positivity.\n* Have a positive Hepatitis C virus (HCV) antibody (Ab) test. Participants with a positive HCV Ab test at screening can be included only if a confirmatory HCV ribonucleic acid (RNA) test is negative.\n* Have a known clinically significant gastric emptying abnormality, have undergone gastric bypass (bariatric) surgery or restrictive bariatric surgery or chronically take drugs that directly affect GI motility.\n* Have had within 3 months prior to screening:\n\n  * acute myocardial infarction\n  * congestive heart failure New York Heart Association (NYHA) class III or IV, and\u002For\n  * cerebrovascular accident \\[stroke\\]\n  * coronary artery revascularisation\n  * hospitalization hospitalisation for unstable angina\n  * hospitalization hospitalisation due to congestive heart failure.\n* Have a history of additional risk factors for Torsades de Pointes (for example, heart failure, hypokalaemia, family history of Long QT Syndrome), as judged by the investigator.\n* Have a 12-lead ECG abnormality at screening that, in the opinion of the investigator, increases the risks associated with participating in the study or may confound electrocardiogram (ECG) data analysis.\n* Have a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome Type 2 (MEN 2).\n* Have an active or untreated malignancy or have been in remission from a clinically significant malignancy for \\\u003C5 years prior to screening. Exceptions:\n\n  * basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of metastatic disease for 3 years\n  * cervical carcinoma in situ, with no evidence of recurrence within the 5 years prior to baseline, or\n  * in situ prostate cancer.\n* Have, in the opinion of the investigator, evidence of significant, uncontrolled endocrine abnormality, for example, thyrotoxicosis or adrenal crisis.\n* Have a prior or planned surgical treatment for obesity.\n* Have a prior or planned endoscopic and\u002For device-based therapy for obesity.\n* Have taken any glucose-lowering medications other than metformin, DPP IV inhibitors, sulfonylureas and\u002For SGLT-2 inhibitors, regardless of the indication for use, any time within the 3 months prior to screening.\n* Have taken prescribed or over-the-counter (OTC) medications, either approved or unapproved, or alternative remedies, including herbal or nutritional supplements, intended to promote body weight reduction, within 3 months prior to screening.\n* Have evidence of human immunodeficiency virus (HIV) infection and\u002For positive human HIV antibodies.\n* Have a calcitonin level at screening of ≥35.0 nanograms per liter (ng\u002FL), \\[≥35.0 picograms per milliliter (pg\u002FmL)\\].",{"count":185,"type":21},95,[187],"PHASE1","The primary objective of Study GZQG is to compare the effect of retatrutide and placebo on total clamp disposition index (cDI) after 28 weeks of treatment.",[190,37],"Diabetes Mellitus","2026-02-27",{"date":193,"type":64},"2026-03-03",{"date":195,"type":64},"2025-06-02",{"date":197,"type":21},"2026-11",{"name":199,"class":200},"Eli Lilly and Company","INDUSTRY",{"id":202,"slug":203,"hasResults":12,"nctId":204,"briefTitle":205,"officialTitle":206,"acronym":207,"eligibilityCriteria":208,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":209,"enrollmentInfo":210,"targetDuration":4,"studyType":22,"phases":212,"briefSummary":214,"conditions":215,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":218,"lastUpdatePostDateStruct":219,"startDateStruct":221,"completionDateStruct":223,"leadSponsor":225,"locationsCount":127},"100611988","phase-2-the-effect-of-colchicine-on-insulin-sensitivity-in-individuals-with-type-1-diabetes-and-systemic-low-grade-inflammation-100611988","NCT07247734","The Effect of Colchicine, on Insulin Sensitivity in Individuals With Type 1 Diabetes and Systemic Low-grade Inflammation","The Effect of Colchicine, on Insulin Sensitivity in Individuals With Type 1 Diabetes and Systemic Low-grade Inflammation: A Randomized, Double-Blind, Placebo-Controlled, Investigator-Initiated Trial","INS1GHT","Inclusion Criteria:\n\n* Type 1 diabetes for more than five years according to World Health Organization criteria and c-peptid \\\u003C200 pmol\u002FL\n* Age 18-80 years\n* User of a continuous glucose monitor (CGM) system\n* Glycated hemoglobin A1c (HbA1c) 42-75 mmol\u002Fmol\n* Stable insulin therapy (defined as no change in insulin brand and no newly initiated Continuous subcutaneous insulin infusion (CSII) or Multiple dose injection (MDI) therapy) and, if applicable, stable usage of glucose monitoring technology (e.g., continuous glucose monitor or intermittently scanned continuous glucose monitor) ≥ 3 months with either multiple daily injections or continuous subcutaneous insulin infusion\n* Estimated glomerular filtration rate ≥ 60 mL\u002Fmin\u002FL\u002F1.73 m²\n* Estimated glucose disposal rate (eGDR)\\* \\\u003C 8 mg\u002Fkg\u002Fmin OR insulin usage of ≥1 IU\u002Fkg pr day\n* C-reactive protein (CRP) hsCRP ≥ 2 mg\u002FL, (measured by high-sensitivity assay)\\*\\*\n\nExclusion Criteria:\n\n* Hypoglycaemia unawareness (inability to register low blood glucose) ad modum Pedersen-Bjergaard, 24 unless the individual uses a continuous glucose monitor with alarm function\n* Liver disease with elevated plasma alanine aminotransferase (ALT) \\> three times the upper limit of normal (measured at screening visit with the possibility of one repeat analysis within seven days, and the last measured value as being conclusive)\n* History of cirrhosis, chronic active hepatitis, or severe hepatic disease\n* Inflammatory bowel disease or chronic diarrhoea\n* Pre-existing progressive neuromuscular disease or individuals with creatinine kinase levels \\> three times the upper limit of normal (measured at screening visit with the possibility of one repeat analysis within a week, and the last measured value as being conclusive)\n* Cancer or lymphoproliferative disease unless in complete remission for \\> 5 years\n* Blood dyscrasias (e.g., myelodysplastic syndromes or related haematological disorders)\n* Leukocyte cell count \\\u003C 3.0 X 109\u002FL\n* Thrombocyte count \\\u003C 110 X 109\u002FL\n* Immunosuppressive therapy or state of chronic immunodeficiency, including infection with human immunodeficiency virus (HIV)\n* Treatment with anti-inflammatory drugs (e.g., non-steroidal anti-inflammatory drugs (NSAID), acetylsalicylic acid (ASA), prednisone) or whole-body topical steroid during the study or within four weeks before study start. Inhaled steroids are allowed. Short term oral NSAID treatment (≤ 3 days) within four weeks before study start or during the study period is allowed. Treatment of ASA is allowed for up to 1000 mg daily.\n* Treatment with colchicine within 60 days of screening visit\n* Known or suspected hypersensitivity to colchicine\n* Treatment with glucose lowering drugs other than insulin (e.g., Glucagon Like Peptide 1 (GLP-1) receptor agonists, metformin, selective sodium glucose cotransporter-2 (SGLT2)-inhibitors) during the study period or within four weeks before study start\n* Haemodialysis or peritoneal dialysis therapy (since colchicine cannot be removed by dialysis or exchange transfusion)\n* Treatment with a P-glycoprotein inhibitor (e.g., azithromycin and verapamil) or a strong CYP3A4 inhibitor (e.g., clarithromycin and ritonavir)\n* Intake of grapefruit juice\n* Other concomitant disease or treatment that according to the investigator's assessment makes the individual unsuitable for study participation\n* Alcohol\u002Fdrug abuse (assessed by the investigator)\n* Regarding fertile women:\n\n  * A woman is considered of childbearing potential (WOCBP), i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile. Permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy.\n  * Sterilised or postmenopausal women (no menses for 12 months without an alternative medical cause) can be included without the human chorionic gonadotrophin (hCG)-testing during the trial period\n  * Women who are pregnant, intend to become pregnant, or are breastfeeding will not be included in the study\n  * Female of childbearing potential: must use highly effective contraceptives during the trial and three months after the trial. To exclude pregnancy, urine hCG tests are performed in relation to all visits (V1-V5) and to the phone call in the washout period (P2) and there will be instructions to ensure monthly testing three months after the end of the trial.\n  * The following contraceptive methods are considered highly effective and thus adequate for study enrolment for females if maintained throughout the study duration and three months after the trial: Combined hormonal contraception associated with inhibition of ovulation (containing estrogen and progestogen administered oral, intravaginal or transdermal). Progestogen-only hormonal contraception associated with inhibition of ovulation (admninistered oral, injectable or implantable). Intrauterine device (IUD). Intrauterine hormone-releasing system. Bilateral tubal occlusion. Vasectomised partner. Sexual abstinence (sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatments. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the subject).\n  * Male participants with partners of childbearing potential: must either use a condom or ensure that their partner uses a highly effective contraceptive method during the trial and six months after the trial.\n* Pregnant or nursing women\n* Participants unable to speak or understand Danish\n* Receipt of any investigational drug within 30 days prior to visit 1\n* Simultaneous participation in any other clinical intervention trial","80 Years",{"count":211,"type":21},26,[213],"PHASE2","The aim for this clinical trial is to evaluate if colchicine in addition to standard of care improves insulin sensitivity in individuals with type 1 diabetes, systemic low-grade inflammaiton and reduced insulin sensitivity. The insulin sensitivity will be evaluated by a hyperinsulinemic, euglycemic clamp.",[216,217,37],"Type 1 Diabetes","Chronic Inflammation","2025-12-22",{"date":220,"type":64},"2025-12-23",{"date":222,"type":64},"2025-12-01",{"date":224,"type":21},"2027-06-22",{"name":226,"class":71},"Asger Lund, MD",{"id":228,"slug":229,"hasResults":12,"nctId":230,"briefTitle":231,"officialTitle":231,"acronym":4,"eligibilityCriteria":232,"healthyVolunteers":106,"sex":17,"minAge":233,"maxAge":234,"enrollmentInfo":235,"targetDuration":4,"studyType":22,"phases":237,"briefSummary":238,"conditions":239,"keywords":243,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":245,"lastUpdatePostDateStruct":246,"startDateStruct":247,"completionDateStruct":249,"leadSponsor":251,"locationsCount":72},"100515529","the-sweet-kids-study-stevia-on-weight-and-energy-effect-over-time-100515529","NCT05992688","The Sweet Kids Study (Stevia on Weight and Energy Effect Over Time)","Inclusion Criteria\n\n* Age 8-12 years\n* Normal weight: BMI percentile ≥5th to \\\u003C85th\n* Excessive weight: BMI percentile ≥ 85th and \\\u003C140% of the 95th percentile or BMI ≥35 to \\\u003C40 kg\u002Fm2\n* Current consumption of sugar sweetened beverages (≥2 times \u002Fwk)\n* Low consumption of non-nutritive sweeteners (≤ 3 time\u002Fwk)\n* Willingness to consume experimental products Exclusion Criteria\n* Children with class 3 obesity (i.e., BMI ≥ 140% of the 95th percentile or BMI ≥ 40.0 kg\u002Fm2)\n* Dislike of experimental beverage taste (assessed at initial visit)\n* Asthma that requires daily use of inhalers to keep symptoms under control.\n* Asthma that requires use of rescue inhalers (e.g., albuterol) \\>2 days per week\n* Exercise induced asthma.\n* Autism spectrum disorder (e.g., Autistic disorder, Rett disorder, Asperger disorder, childhood disintegrative disorder, pervasive developmental disorder not otherwise specified (PDD-NOS).\n* Attention deficit hyperactivity disorder (ADHD) currently under medication.\n* Oppositional defiant disorder (ODD).\n* Epilepsy.\n* Cancer.\n* Chronic kidney disease.\n* Endocrine disorder (e.g., hypothyroidism and growth hormone deficiency).\n* Autoimmune diseases (e.g., lupus, thyroiditis, juvenile idiopathic arthritis)\n* Bleeding disorders (e.g., hemophilia)\n* Chronic infections (e.g., HIV, hepatitis B, hepatitis C).\n* Mental health disorders (e.g., depression and anxiety).\n* Type 2 and type 1 diabetes mellitus.\n* Other pre-existing medical conditions or medications as determined by the investigators to affect the outcomes of interest.\n* If, during the screening or consent process, the parent or child expresses refusal to have blood drawn. However, participants may remain in the study if after initially agreeing to the blood draw and enrolling they change their minds and choose not to allow blood draws or if blood draws are unsuccessful.\n* Dislike of study products assessed at initial visit.\n* Fasting glucose ≥126 mg\u002Fdl at enrollment.\n* Fasting A1C ≥6.5% at enrollment\n* Less than 2 months since completion of antibiotics","8 Years","12 Years",{"count":236,"type":21},150,[24],"This is an 8 to14-week three-arm randomized controlled in children 8 to 12 years old.\n\nThe main purpose of the study is to evaluate if stevia has benefits for weight control and metabolic function relative to caloric sweeteners, and whether it provides benefits in this regard similar to water.",[114,37,240,241,242],"Weight Gain","Blood Pressure","Lipoproteins",[244],"Cardiometabolic health","2025-12-16",{"date":218,"type":64},{"date":248,"type":64},"2023-09-19",{"date":250,"type":21},"2026-11-30",{"name":252,"class":71},"Arkansas Children's Hospital Research Institute",{"id":254,"slug":255,"hasResults":12,"nctId":256,"briefTitle":257,"officialTitle":257,"acronym":258,"eligibilityCriteria":259,"healthyVolunteers":106,"sex":17,"minAge":18,"maxAge":260,"enrollmentInfo":261,"targetDuration":4,"studyType":22,"phases":263,"briefSummary":264,"conditions":265,"keywords":267,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":273,"lastUpdatePostDateStruct":274,"startDateStruct":276,"completionDateStruct":278,"leadSponsor":280,"locationsCount":127},"100558361","impact-of-circulating-and-tissue-specific-lipids-on-vascular-function-and-insulin-sensitivity-in-chronic-night-shift-workers-100558361","NCT06550115","Impact of Circulating and Tissue-specific Lipids on Vascular Function and Insulin Sensitivity in Chronic Night Shift Workers","SHINE","Inclusion Criteria:\n\n* 18-65 years old\n* worked the night shift for the last 1 year or more,\n* habitually sleep 5-9 hours per 24h period (night shift workers typically experience chronic insufficient sleep),\n* body mass index (BMI) of 20.0 - 35.0 kg\u002Fm2 and weight stable (plus or minus 5% of current body weight in the last 6 months); sedentary to mild physical activity level (less than 2 days of planned exercise per week);\n\nExclusion Criteria:\n\n* existing diagnosed sleep or eating disorder (e.g. obstructive sleep apnea \\[OSA\\], periodic limb movements of sleep \\[PLMS\\], narcolepsy, travel more than 1 time zone in 3 weeks before the study; anorexia nervosa, more than one food allergy to maintain flexibility in diet planning);\n* following any TRE (time-restricted eating) or intermittent fasting plan in the last year;\n* following any special diet plan, like paleo, keto, gluten-free or vegan, that can affect the primary lipid outcome measures in the last 6 months; any clinically significant surgical condition within the last year;\n* diagnosed diabetes or cardiovascular disease\n\n  * The prevalence of insomnia in shift workers is fairly high, ranging from 12.8% to 76.4%, which is higher than estimated for the general population. Insomnia itself is associated with elevated neural cardiovascular responsiveness to stress compared to people without insomnia. Thus, since excessive sleepiness and symptoms of insomnia may be present in night shift workers they will not be exclusionary.","65 Years",{"count":262,"type":21},50,[24],"People who experience repeated bouts of circadian misalignment, such as shift workers, are at higher risk of cardiovascular disease (CVD) and Type 2 diabetes (T2D) compared to daytime workers. However, the mechanism(s) by which shift work and associated circadian misalignment increase CVD and T2D risk are unknown. This project will examine whether elevated plasma lipids are a mechanism by which circadian misalignment impairs vascular function, insulin sensitivity, glucose homeostasis and muscle lipid accumulation, which could be targeted to prevent and treat cardiometabolic disease in people who chronically experience circadian misalignment, which includes more than 20% of the US workforce.",[266,39,37,241],"Circadian Rhythm Sleep Disorder of Shift Work Type",[268,89,269,270,271,272],"Shift work","Blood sugar","Metabolism","Lipids","Blood pressure","2025-12-15",{"date":275,"type":64},"2025-12-17",{"date":277,"type":64},"2024-03-01",{"date":279,"type":21},"2029-06",{"name":281,"class":71},"Colorado State University",{"id":283,"slug":284,"hasResults":12,"nctId":285,"briefTitle":286,"officialTitle":287,"acronym":4,"eligibilityCriteria":288,"healthyVolunteers":12,"sex":17,"minAge":135,"maxAge":4,"enrollmentInfo":289,"targetDuration":4,"studyType":22,"phases":291,"briefSummary":292,"conditions":293,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":297,"lastUpdatePostDateStruct":298,"startDateStruct":300,"completionDateStruct":302,"leadSponsor":304,"locationsCount":127},"100465161","non-nutritive-sweetener-consumption-and-glucose-homeostasis-in-older-adults-with-prediabetes-100465161","NCT05337098","Non-Nutritive Sweetener Consumption and Glucose Homeostasis in Older Adults With Prediabetes","Non-Nutritive Sweetener Consumption (Aspartame and Sucralose) and Glucose Homeostasis in Older Adults With Prediabetes","Inclusion Criteria:\n\n* Age 40+ years\n* Prediabetic (fasting glucose concentration of 100-125 mg\u002FdL, 2-hour oral glucose tolerance test glucose concentration of 140-199 mg\u002FdL, or a HbA1c value of 5.7% to 6.4%)\n* Weight stable for previous 6 months (±2 kg)\n* BMI \\\u003C40 kg\u002Fm2\n* Sedentary to recreationally active\n* No plans to gain\u002Flose weight or change physical activity level\n* Willing to pick up food daily and consume foods provided for an 8-week period\n* Verbal and written informed consent\n* Approval by Medical Director\n* Consume less than one serving of non-nutritive sweetener per week\n\nExclusion Criteria:\n\n* BMI \\>40 kg\u002Fm2\n* Diabetes or diabetes medication\n* Antibiotic, prebiotic or prebiotic use in prior 3 months\n* Uncontrolled hypertension (blood pressure (BP) \\> 159\u002F99 mmHg)\n* Diagnosed inflammatory bowel disease\n* Past or current heart diseases, stroke, respiratory disease, endocrine or metabolic disease, or hematological-oncological disease\n* Vegetarian or vegan\n* Pregnant or plans to become pregnant\n* Breastfeeding\n* Food allergies or aversions, Phenylketonuria (PKU)\n* Estrogen or testosterone usage",{"count":290,"type":21},30,[24],"Animal and observational research in humans suggest that specific types of non-nutritive sweeteners (NNS) may impair glycemic control. However, whether NNS consumption impacts glucose homeostasis in middle-aged\u002Folder adults with prediabetes is unknown, and potential mechanisms by which this could occur have yet to be identified. The overall objective of this R21 proposal is to establish proof-of-concept for alterations in glucose homeostasis following intake of sucralose, but not aspartame, in middle-aged\u002Folder adults with prediabetes compared to a eucaloric diet with no NNS.",[294,295,37,296],"Continuous Glucose Monitoring","Oral Glucose Tolerance","Inflammatory Markers","2025-12-03",{"date":299,"type":64},"2025-12-04",{"date":301,"type":64},"2023-04-18",{"date":303,"type":21},"2026-02-28",{"name":305,"class":71},"Virginia Polytechnic Institute and State University",{"id":307,"slug":308,"hasResults":12,"nctId":309,"briefTitle":310,"officialTitle":311,"acronym":312,"eligibilityCriteria":313,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":314,"targetDuration":4,"studyType":22,"phases":315,"briefSummary":316,"conditions":317,"keywords":320,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":322,"lastUpdatePostDateStruct":323,"startDateStruct":324,"completionDateStruct":326,"leadSponsor":328,"locationsCount":127},"100613341","effect-of-physiologic-insulin-administration-on-insulin-sensitivity-and-cognition-100613341","NCT07265323","Effect of Physiologic Insulin Administration on Insulin Sensitivity and Cognition","Effect of Physiologic Insulin Intervention on Insulin Sensitivity and Cognition","MIND-IT","Inclusion Criteria:\n\n* Mini Mental State Examination (MMSE) score \\\u003C 25\n\nExclusion Criteria:\n\n* On daily medication for the specific treatment of anxiety including benzodiazepines.\n* An infant, child, or teenager\n* A pregnant woman\n* A prisoner\n* Having any condition that impedes testing of the study hypothesis or are otherwise deemed to be unsuitable (determined by the investigative team).",{"count":159,"type":21},[24],"The goal of this clinical trial is to determine if a weekly delivery of insulin at short intervals lasting up to 2 hours can improve insulin sensitivity and cognition in adults with Alzheimer's Disease. It will also provide information about the safety and feasibility of this intervention.\n\nThe main questions it aims to answer are:\n\nDoes the intervention improve insulin sensitivity (how the body uses glucose)?\n\nDoes the intervention improve cognition, measured by the Montreal Cognitive Assessment (MoCA) and the Revised Memory and Behavior Problems Checklist (RMBPC)?\n\nWhat changes occur in brain glucose uptake (FDG-PET)?\n\nParticipants will:\n\nReceive the intervention once a week for 6 months, with each session lasting up to 2 hours\n\nComplete cognitive assessments. Adverse events will be assessed throughout the study.",[318,319,37],"Alzheimer s Disease","Alzheimer Blood Biomarkers",[321,37],"Alzheimer's disease","2025-12-02",{"date":299,"type":64},{"date":325,"type":21},"2025-12",{"date":327,"type":21},"2027-05",{"name":329,"class":71},"Pennington Biomedical Research Center",{"id":331,"slug":332,"hasResults":12,"nctId":333,"briefTitle":334,"officialTitle":335,"acronym":4,"eligibilityCriteria":336,"healthyVolunteers":106,"sex":337,"minAge":338,"maxAge":339,"enrollmentInfo":340,"targetDuration":4,"studyType":22,"phases":341,"briefSummary":342,"conditions":343,"keywords":344,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":222,"lastUpdatePostDateStruct":350,"startDateStruct":351,"completionDateStruct":353,"leadSponsor":355,"locationsCount":127},"100575731","physical-activity-and-insulin-sensitivity-dynamics-100575731","NCT06776094","Physical Activity and Insulin Sensitivity Dynamics","The Significance of Physical Activity for Insulin Signaling Dynamics and Insulin Sensitivity","Inclusion Criteria:\n\n* Healthy individuals (no known diseases)\n* No use of medication\n* Non-smokers\n* Male\n* Aged 22-35 years\n* Fitness level (VO2max, i.e., maximal oxygen uptake) between 30-50 mL O2\u002Fmin\u002Fkg\n* BMI between 28 and 35\n\nExclusion Criteria:\n\n* Women\n* Failure to meet all inclusion criteria\n* Physical activity level (e.g., running, cycling, fitness, etc.) exceeding 6 hours per week\n* Acute illness within 2 weeks prior to the study days\n* Use of recreational drugs within 2 weeks prior to the study days","MALE","22 Years","35 Years",{"count":159,"type":21},[24],"The study investigates the role of one single bout of exercise in mediating enhancement of muscle insulin sensitivity following a single bout of exercise. Furthermore, the study is aiming to elucidate the temporal development in insulin signaling, at the early timepoints of insulin stimulation that may be responsible for the enhanced muscle insulin sensitivity.\n\nThis will be investigated in young healthy males subjected to a one-legged knee-extensor exercise followed by a hyperinsulinemic-euglycemic clamp, a setup known to enhance muscle insulin sensitivity.",[37],[345,346,347,348,349],"Exercise","Muscle insulin sensitivity","Muscle glucose uptake","GLUT4","Phosphoproteomics",{"date":322,"type":64},{"date":352,"type":64},"2025-05-05",{"date":354,"type":21},"2027-01",{"name":356,"class":71},"University of Copenhagen",{"id":358,"slug":359,"hasResults":12,"nctId":360,"briefTitle":361,"officialTitle":361,"acronym":4,"eligibilityCriteria":362,"healthyVolunteers":106,"sex":363,"minAge":364,"maxAge":135,"enrollmentInfo":365,"targetDuration":4,"studyType":22,"phases":366,"briefSummary":367,"conditions":368,"keywords":369,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":371,"lastUpdatePostDateStruct":372,"startDateStruct":374,"completionDateStruct":376,"leadSponsor":378,"locationsCount":4},"100603650","insulin-sensitivity-and-testosterone-response-to-aerobic-exercise-versus-added-sugar-elimination-in-polycystic-ovary-syndrome-women-100603650","NCT07139275","Insulin Sensitivity and Testosterone Response to Aerobic Exercise Versus Added Sugar Elimination in Polycystic Ovary Syndrome Women","Inclusion Criteria: sedentary overweight or obese females aged 25-40 years old with polycystic ovarian syndrome with low insulin sensitivity levels with a body mass index of 26-40 and all were diagnosed as having high, normal, or mildly elevated levels of homeostatic model assessment for insulin resistance and had none of the exclusion criteria could be included in this study.\n\nExclusion Criteria: patients with orthopaedic disorders that could impede the ability to walk or exercise, cardiac diseases that could interfere with their ability to exercise","FEMALE","25 Years",{"count":84,"type":21},[24],"the aim of this study is to investigate the effect of aerobic exercise versus the effect of added sugar elimination on the insulin sensitivity and testosterone levels in females with polycystic ovarian syndrome via measuring the level of 6 hours fasting HOMA-IR and free testosterone before and after 3 months from starting the protocol. All patients were diagnosed as polycystic ovary syndrome with low insulin sensitivity levels",[37],[370],"inulin senstivity, testosterone, aerobic exercise","2025-08-17",{"date":373,"type":64},"2025-08-24",{"date":375,"type":21},"2025-08-20",{"date":377,"type":21},"2025-12-30",{"name":379,"class":71},"Cairo University",{"id":381,"slug":382,"hasResults":12,"nctId":383,"briefTitle":384,"officialTitle":385,"acronym":386,"eligibilityCriteria":387,"healthyVolunteers":106,"sex":17,"minAge":18,"maxAge":339,"enrollmentInfo":388,"targetDuration":4,"studyType":22,"phases":390,"briefSummary":391,"conditions":392,"keywords":393,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":394,"lastUpdatePostDateStruct":395,"startDateStruct":397,"completionDateStruct":399,"leadSponsor":401,"locationsCount":127},"100436675","countermeasures-to-circadian-misalignment-100436675","NCT04966351","Countermeasures to Circadian Misalignment","Time-restricted Feeding to Mitigate Metabolic Impairments During Circadian Misalignment","C2CM","Inclusion Criteria:\n\n1. 18-35 old; men and women; equal numbers of women and men will be included.\n2. Body Mass Index (BMI) between 20.0 and 24.9 (\"normal\" weight).\n3. Physical activity history: inactive to habitual moderate physical activity level\n4. Sleep\u002Fwake history: habitual sleep duration between 7-9.25 hours.\n5. Altitude history: Potential subjects must have lived at Denver altitude or higher for at least 3 months prior to inpatient stay.\n\nExclusion Criteria:\n\n1. Any clinically significant medical, psychiatric, or sleep disorder\n2. Use of prescribed medications\u002Fsupplements\u002Fillicit drugs within one month prior to study\n3. History of shift work in year prior to study, or travel more than one time zone in three weeks prior to study. \\[NOTE: Subjects can be studied at a later date.\\]\n4. Women with history of prior gynecological pathology, \\\u003C1 year post-partum, breast-feeding and\u002For pregnant.\n5. Non-English speakers will be excluded, as we do not have access to a translator who could rely accurate information to the participant for the consent or throughout the study.",{"count":389,"type":21},32,[24],"Insufficient sleep and circadian misalignment are independent risk factors for the development of obesity and diabetes, yet few strategies exist to counter metabolic impairments when these behaviors are unavoidable.\n\nThis project will examine whether avoiding food intake during the biological night can mitigate the impact of circadian misalignment on metabolic homeostasis in adults during simulated night shift work. Findings from this study could identify a translatable strategy to minimize metabolic diseases in populations that include anyone working nonstandard hours such as police, paramedics, firefighters, military personnel, pilots, doctors and nurses, truck drivers, and individuals with sleep disorders.",[266,39,37],[268,89,269,270],"2025-07-21",{"date":396,"type":64},"2025-07-24",{"date":398,"type":64},"2021-07-07",{"date":400,"type":21},"2026-06-30",{"name":281,"class":71},{"id":403,"slug":404,"hasResults":12,"nctId":405,"briefTitle":406,"officialTitle":406,"acronym":407,"eligibilityCriteria":408,"healthyVolunteers":12,"sex":17,"minAge":234,"maxAge":364,"enrollmentInfo":409,"targetDuration":4,"studyType":22,"phases":410,"briefSummary":411,"conditions":412,"keywords":416,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":422,"lastUpdatePostDateStruct":423,"startDateStruct":425,"completionDateStruct":427,"leadSponsor":429,"locationsCount":72},"100444280","phase-1-manatee-t1d-metformin-and-automated-insulin-delivery-system-effects-on-renal-vascular-resistance-insulin-sensitivity-and-cardiometabolic-function-in-youth-with-type-1-diabetes-100444280","NCT05065372","MANATEE-T1D: Metformin ANd AutomaTEd Insulin Delivery System Effects on Renal Vascular Resistance, Insulin Sensitivity, and Cardiometabolic Function in Youth With Type 1 Diabetes","MANATEE-T1D","Inclusion Criteria:\n\n* T1D and using an automated insulin delivery system or multiple daily insulin injections\u002Fmanual insulin pump plus continuous glucose monitor for \\> 6 months\n* Age 12-25 years\n* Use of an automated insulin delivery system or multiple daily insulin injections plus a continuous glucose monitor or an insulin pump in manual mode plus a continuous glucose monitor for \\> 6 months\n* Hemoglobin A1c \\\u003C 11%\n* No recent episodes of diabetic ketoacidosis (DKA) or hyperglycemic hyperosmolar syndrome (HHS) (within 30 days)\n* Pubertal (Tanner stage ≥ 2)\n* Weight \\> 54 kg and BMI \\> 5th percentile for age and sex\n\nExclusion Criteria:\n\n* Blood pressure \\> 140\u002F90 mm Hg\n* Hemoglobin \\\u003C 9 g\u002FdL\n* Estimated glomerular filtration rate \\\u003C 60 mL\u002Fmin\u002F1.73 m2 or serum creatinine \\> 1.2 mg\u002FdL or history of urinary albumin to creatinine ratio ≥ 300mg\u002Fg or history of acute kidney injury\n* Use of anti-diabetic agents except insulin, angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARB's), diuretics, daily non-steroidal anti-inflammatory drugs (NSAIDs) or aspirin, sulfonamides, procaine, thiazosulfone or probenecid\n* Seafood or iodine allergy\n* Pregnancy or breast feeding for females",{"count":84,"type":21},[187],"Diabetic kidney disease and cardiovascular disease remain the leading causes of morbidity and mortality in people with type 1 diabetes and are exacerbated with longer duration of diabetes and time outside goal glycemic range. Yet, type 1 diabetes is a complex disease with pathophysiology that extends beyond beta-cell injury and insulin deficiency to include insulin resistance and renal vascular resistance, factors that accelerate cardiovascular disease risk. We have shown that metformin improved peripheral insulin sensitivity and vascular stiffness in youth with type 1 diabetes on multiple daily insulin injections or standard insulin pumps. However, metformin's effect on kidney and endothelial outcomes, and the effects of type 1 diabetes technologies, with or without metformin, on any cardiovascular or kidney outcome, remains unknown. Automated insulin delivery systems combine an insulin pump, continuous glucose monitor, and control algorithm to modulate background insulin delivery and decrease peripheral insulin exposure while improving time in target range and reducing hypoglycemia. We hypothesize that automated insulin delivery systems, particularly when combined with metformin, may modulate renal vascular resistance and insulin sensitivity, thereby impacting cardiometabolic function. MANATEE-T1D is a randomized, double-blind, placebo-controlled trial of 4 months of metformin 2,000 mg daily in 40 youth aged 12-25 years with type 1 diabetes on automated insulin delivery systems vs. 20 control youth with type 1 diabetes on multiple daily injections plus a continuous glucose monitor or an insulin pump in manual mode plus a continuous glucose monitor which will assess for changes in calculated renal vascular resistance and gold standard measures of whole-body and adipose insulin sensitivity, arterial stiffness, and endothelial function.",[216,413,414,415,37],"Diabetic Kidney Disease","Cardiovascular Diseases","Endothelial Dysfunction",[417,418,419,420,421],"Type 1 diabetes","Youth","Insulin sensitivity","Cardiovascular function","Diabetic kidney disease","2025-06-10",{"date":424,"type":64},"2025-06-13",{"date":426,"type":64},"2022-07-01",{"date":428,"type":21},"2027-07-31",{"name":430,"class":71},"Kalie Tommerdahl",{"id":432,"slug":433,"hasResults":12,"nctId":434,"briefTitle":435,"officialTitle":435,"acronym":436,"eligibilityCriteria":437,"healthyVolunteers":12,"sex":17,"minAge":438,"maxAge":439,"enrollmentInfo":440,"targetDuration":4,"studyType":442,"phases":4,"briefSummary":443,"conditions":444,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":447,"lastUpdatePostDateStruct":448,"startDateStruct":449,"completionDateStruct":451,"leadSponsor":453,"locationsCount":127},"100408293","pubertal-blockade-and-estradiol-effects-on-cardiometabolic-health-for-transitioning-youth-100408293","NCT04596592","Pubertal Blockade and Estradiol Effects on Cardiometabolic Health for Transitioning Youth","PUBERTY","Inclusion Criteria (transgender females):\n\n* Identify as a transgender female\n* Age 13-16 years at the time of enrollment\n* If on a gonadotropin releasing hormone analogue, \\> 6 months exposure\n* Plan to start estradiol clinically in \\\u003C 4 months\n\nInclusion Criteria (cisgender males and females):\n\n* Males and females ages 13-16 years\n\nExclusion Criteria:\n\n* Cognitive, psychiatric, or physical impairment resulting in inability to tolerate the study procedures\n* Antipsychotic medication use\n* Type 1 or 2 diabetes (by medical history)\n* Polycystic ovarian syndrome (PCOS for cisgender females)\n* Hypertension (resting BP ≥ 140\u002F90 mm\u002FHg)\n* Weight\\> 400 lbs\n* On oral progesterone medications (including oral progesterone or progestin, combined oral contraceptives or etonogestrel implant)\n* Pregnancy (for cisgender females)","13 Years","16 Years",{"count":441,"type":21},90,"OBSERVATIONAL","To evaluate the effect of estradiol with or without a prior gonadotropin releasing hormone analogue on insulin sensitivity and vascular function in transgender females compared to cisgender controls.",[445,446,37],"Transgenderism","Gender Dysphoria","2025-06-05",{"date":422,"type":64},{"date":450,"type":64},"2021-02-15",{"date":452,"type":21},"2026-07-31",{"name":99,"class":71},{"id":455,"slug":456,"hasResults":12,"nctId":457,"briefTitle":458,"officialTitle":458,"acronym":4,"eligibilityCriteria":459,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":209,"enrollmentInfo":460,"targetDuration":4,"studyType":22,"phases":462,"briefSummary":463,"conditions":464,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":352,"lastUpdatePostDateStruct":465,"startDateStruct":467,"completionDateStruct":469,"leadSponsor":471,"locationsCount":127},"100519359","mechanisms-of-ultrasound-neuromodulation-effects-in-diabetes-100519359","NCT06042517","Mechanisms of Ultrasound Neuromodulation Effects in Diabetes","Inclusion Criteria:\n\n* Type 2 diabetic (T2D) subjects must be aged 18-80 and must be able to provide written informed consent\n* All subjects must have had T2D for at least 3 months prior to study enrollment. All subjects must be either on diet and exercise or oral antidiabetic agents alone, not on insulin or any form of insulin or GLP-1 receptor agonists.\n* Subjects must demonstrate:\n\n  1. A past medical history of abnormal glucose control and carry a diagnosis of T2D according to current ADA criteria:\n\n     * A fasting plasma glucose (FPG) level of 126 mg\u002FdL (7.0 mmol\u002FL) or higher, or\n     * A 2-hour plasma glucose level of 200 mg\u002FdL (11.1 mmol\u002FL) or higher during a 75-g oral glucose tolerance test (OGTT), or\n     * A random plasma glucose of 200 mg\u002FdL (11.1 mmol\u002FL) or higher in a patient with classic symptoms of hyperglycemia or hyperglycemic crisis or\n     * A hemoglobin A1c (HbA1c) level of 6.5% or higher.\n  2. Be willing to carry a continuous glucose monitor for at least 10 days.\n  3. Be willing to follow all required instructions by study personnel and appear for the required laboratory assessments, including euglycemic clamps and OGTT.\n\nExclusion Criteria:\n\n* BMI \\>40kg\u002Fm2.\n* Untreated proliferative retinopathy\n* Creatinine clearance \\\u003C 60 ml\u002Fmin\u002F1.73 m2.\n* Serum creatinine ≥1.5 mg\u002FdL\n* Positive pregnancy test, or presently breast-feeding, or failure to follow effective contraceptive measures\n* Active infection including hepatitis C, hepatitis B, HIV,\n* Any history of Active alcohol abuse\n* History of non-adherence to prescribed regimens\n* Baseline Hgb \\\u003C 10.5 g\u002FdL in females, or \\\u003C 13 g\u002FdL in males\n* History of coagulopathy or medical condition requiring long-term anticoagulant therapy (low-dose aspirin treatment is allowed)\n* Co-existing cardiac disease with active medication titration. Patients on stable meds without active cardiac complications permitted.\n* Liver function tests outside of 3xUL of normal range\n* GI disorders potentially interfering with the ability to absorb oral medications and h\u002Fo upper GI surgery that might have changed anatomy in the target areas.\n* Any medical condition or medication that, in the opinion of the investigators, will interfere with the safe completion of the study or study outcomes.",{"count":461,"type":21},77,[24],"This study aims to evaluate the effect of hepatic ultrasound treatment on changes from baseline in whole-body insulin sensitivity during a hyperinsulinemic, euglycemic clamp (HE Clamp).",[37],{"date":466,"type":64},"2025-05-08",{"date":468,"type":64},"2023-09-30",{"date":470,"type":21},"2027-09-30",{"name":472,"class":71},"Yale University",{"id":474,"slug":475,"hasResults":12,"nctId":476,"briefTitle":477,"officialTitle":477,"acronym":4,"eligibilityCriteria":478,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":479,"targetDuration":4,"studyType":22,"phases":481,"briefSummary":483,"conditions":484,"keywords":486,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":490,"lastUpdatePostDateStruct":491,"startDateStruct":493,"completionDateStruct":495,"leadSponsor":497,"locationsCount":127},"100588327","phase-4-evaluating-the-efficacy-of-topical-insulin-for-the-restoration-of-ocular-surface-interface-in-dry-eye-disease-100588327","NCT06939959","Evaluating the Efficacy of Topical Insulin for the Restoration of Ocular Surface Interface in Dry Eye Disease.","Inclusion Criteria:\n\n* Patients having Schirmer's test values of less than 10mm after 5 minutes of the procedure recording plus a non-invasive tear breakup time (TBUT) of less than 10 seconds and the Ocular Surface Disease Index (OSDI) of more than 32 (diagnosed as dry eye disease as per the operational definition of this study).\n* any gender.\n* aged 18 years and above.\n\nExclusion Criteria:\n\n* Patients with active ocular infection, severe ocular surface disease other than Dry eye disease, and those who have undergone ocular surgery within the past 6 months.\n* Under 18 years old",{"count":480,"type":21},126,[482],"PHASE4","This is a parallel randomized controlled trial for the treatment of dry eye disease. The main objective is to investigate the efficacy and safety of the use of insulin eye drops in the control of moderate-severe dry eye disease. Topical insulin drops will be compared to artificial tears in improving the ocular surface interface in patients with dry eye disease over 1 year period.",[485,37],"Dry Eye",[487,488,489],"DRY EYE DISEASE","Topical Insulin","Ocular Surface Interface restoration","2025-04-15",{"date":492,"type":64},"2025-04-23",{"date":494,"type":64},"2025-04-14",{"date":496,"type":21},"2026-04-20",{"name":498,"class":71},"Khyber Teaching Hospital",{"id":500,"slug":501,"hasResults":12,"nctId":502,"briefTitle":503,"officialTitle":504,"acronym":4,"eligibilityCriteria":505,"healthyVolunteers":12,"sex":17,"minAge":506,"maxAge":507,"enrollmentInfo":508,"targetDuration":4,"studyType":22,"phases":510,"briefSummary":511,"conditions":512,"keywords":516,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":520,"lastUpdatePostDateStruct":521,"startDateStruct":523,"completionDateStruct":525,"leadSponsor":527,"locationsCount":127},"100544247","the-acute-t-rex-timing-of-resistance-exercise-study-100544247","NCT06366399","The Acute T-Rex (Timing of Resistance Exercise) Study","Timing (AM v PM) of Acute Resistance Exercise on Glycemic Control in Older Adults: The Acute T-Rex Study","Inclusion Criteria:\n\n* Men and women, all ethnicities, aged 50-74 years\n* BMI ≥25 kg\u002Fm² and \\\u003C45 kg\u002Fm²\n* Weight stable (less than 5% change in the past 6 months)\n* Generally healthy individuals\n* Not meeting recommended activity guidelines for aerobic or resistance exercise\n\nExclusion Criteria:\n\n* Uncontrolled cardiovascular, metabolic, renal, or pulmonary disease\n* Cancer treatment in the past 5 years\n* Untreated thyroid disease or other medical conditions affecting weight or energy metabolism\n* Current use of weight loss medication or other medications likely to impact energy balance\n* Bariatric surgery or extensive bowel resection in the past 2 years\n* Current or recent history (past 2 years) of eating disorder\n* Diagnosis of insomnia, sleep apnea, or other sleep and circadian disorders\n* Non-English speaking\n* HbA1c \\>6.5%","50 Years","74 Years",{"count":509,"type":21},20,[24],"The primary aim of this study is to evaluate if a single bout of AM vs PM resistance exercise has different effects on insulin sensitivity and sleep. A randomized cross-over trial be used to compare resistance exercise at two different times of the day. Each condition will take place in a laboratory setting. Each condition will consist of exercise, overnight sleep, and oral glucose tolerance tests the following day. The AM exercise will occur \\~1.5 hours after habitual wake, and PM exercise will occur \\~11 hours after habitual wake. After a 2-6 week washout, participants will complete the other condition. The hypothesis is that PM exercise will be more beneficial than AM exercise in improving insulin sensitivity. This study could identify if there is a better time of day to perform resistance exercise to decrease risk of developing Type 2 Diabetes Mellitus.",[41,36,513,514,515,37],"Glucose Intolerance","Sleep Disturbance","Overweight or Obesity",[517,518,89,519],"Resistance Exercise","Strength-training","Circadian Rhythm","2025-04-01",{"date":522,"type":64},"2025-04-03",{"date":524,"type":64},"2023-11-15",{"date":526,"type":21},"2025-12-31",{"name":528,"class":71},"University of Utah",{"id":530,"slug":531,"hasResults":12,"nctId":532,"briefTitle":533,"officialTitle":534,"acronym":4,"eligibilityCriteria":535,"healthyVolunteers":106,"sex":17,"minAge":18,"maxAge":107,"enrollmentInfo":536,"targetDuration":4,"studyType":22,"phases":537,"briefSummary":538,"conditions":539,"keywords":542,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":547,"lastUpdatePostDateStruct":548,"startDateStruct":550,"completionDateStruct":552,"leadSponsor":554,"locationsCount":127},"100553572","effect-of-glp1-receptor-agonist-on-brain-insulin-responsiveness-100553572","NCT06487832","Effect of GLP1 Receptor Agonist on Brain Insulin Responsiveness","Impact of the Incretin System on Brain Insulin Sensitivity in Humans with Normal Weight, Overweight and Obesity","Inclusion Criteria:\n\n* BMI between 18.5 and 24.9 kg\u002Fm2; and between 27.5 kg\u002Fm2 and 40 kg\u002Fm2\n* Written consent to participate in the study\n* Written consent to be informed about incidental findings\n\nExclusion Criteria:\n\n* Type 1 or type 2 diabetes, LADA, MODY, or cardiovascular diseases such as chronic heart failure, myocardial infarction, status post stroke\n* BMI \\\u003C 18.5 or \\> 40 kg\u002Fm2\n* Persons who cannot legally give consent\n* Pregnancy or lactation\n* History of severe mental or somatic disorders including neurological diseases (incl. epileptic seizures)\n* Taking psychotropic drugs\n* Chronic diseases or medication that influence glucose metabolism\n* Regular use of analgesic drugs\n* Previous bariatric surgery\n* Known allergy against one or more of the used agents\n* Acute infection and\u002For antibiotic treatment within the last 4 weeks\n* Hemoglobin values less than 10.5 g\u002Fdl for women, less than 11.5 g\u002Fdl for men\n* Other diseases that in the opinion of the investigator may jeopardize the success of the study or indicate a risk to the volunteer\n* Participation in a lifestyle intervention study or a pharmaceutical study within the last 30 days\n* Metal implants which cannot be removed as pacemakers, artificial heart valve, electrical devices as insulin pumps, large tattoos, retainer over more than 4 teeth, contraceptive coil, implanted magnetic metal parts as screws or plates after a surgery\n* Persons with claustrophobia\n* Persons with tinnitus\n* Weight loss or gain of \\>5% in the last 3 months\n* Pancreatic diseases\n* History or family history of multiple endocrine neoplasia (MEN2) or medullary thyroid cancer\n* History of malignant thyroid disease\n* History of malignant disease in the past 5 years\n* Surgery in the last three months\n* Chronic tobacco use of more than 10 cigarettes\u002Fday\n* Women who do not consent to refrain from breastfeeding until 2 months after the end of the study\n* Women of childbearing age who do not consent to use safe method of contraception from 28 days before until 2 months after the end of the study or refrain from heterosexual intercourse during this time\n* Women of childbearing age who do not consent to take a pregnancy test",{"count":84,"type":21},[24],"The overarching goal of the current study is to investigate the effect of GLP-1 on brain insulin responsiveness in a randomized, single-blinded, within subject cross-over study design. To this end, investigators will compare the effect of the administration of semaglutide versus placebo, followed by an fMRI with administration of intranasal insulin or placebo.",[540,541,37,36],"Normal Weight","Overweight and Obesity",[543,544,545,546],"GLP-1","Brain","functional magnetic resonance imaging","Semaglutide","2025-03-25",{"date":549,"type":64},"2025-03-30",{"date":551,"type":64},"2024-07-01",{"date":553,"type":21},"2027-12-31",{"name":555,"class":71},"University Hospital Tuebingen",{"id":557,"slug":558,"hasResults":12,"nctId":559,"briefTitle":560,"officialTitle":561,"acronym":4,"eligibilityCriteria":562,"healthyVolunteers":106,"sex":17,"minAge":18,"maxAge":157,"enrollmentInfo":563,"targetDuration":4,"studyType":22,"phases":565,"briefSummary":566,"conditions":567,"keywords":572,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":576,"lastUpdatePostDateStruct":577,"startDateStruct":579,"completionDateStruct":581,"leadSponsor":583,"locationsCount":127},"100583627","postprandial-metabolome-and-metabolic-flexibility-100583627","NCT06878781","Postprandial Metabolome and Metabolic Flexibility","Standardized Meals With Different Macronutrient Ratios on the Postprandial Metabolome and Metabolic Flexibility","Inclusion Criteria:\n\n* be over 18 years of age and under 30 years of age;\n* without active drug addictions: smoking, alcoholism, and\u002For drug addiction;\n* in female subjects: regular menstrual cycles;\n* give written consent for their inclusion in the study.\n\nExclusion Criteria:\n\n* subjects with any pathology that requires medication or special treatment, such as type 2 diabetes mellitus, high blood pressure, dyslipidemia, polycystic ovary syn-drome, autoimmune, thyroid, kidney, neurological diseases, and cancer;\n* pregnant or lactating women;\n* subjects with problems with chewing, salivation, and swallowing.\n\nElimination criteria:\n\n* subjects who only have samples (blood and calorimetry) from one study period (fasting or postprandial);\n* subjects who only have samples (blood and calorimetry) of a metabolic challenge;\n* subjects who have an infection at the scheduled appointment;\n* subjects who withdraw their informed consent",{"count":564,"type":21},300,[24],"Metabolic flexibility is a process in which the body can switch energy substrates in different physiological states. This flexibility plays an important role in an individual's health because losing it increases the risk of obesity, metabolic syndrome, insulin resistance, and type 2 diabetes. Considering that humans spend most of their awakening hours in a postprandial (PP) state, an organism's metabolic flexibility (MF) to respond to a standardized meal's consumption would provide information on the individual's metabolic health. The PP response to glucose following an oral glucose tolerance test or consumption of a high-carbohydrate meal is well described; however, few studies assess the FM and PP metabolome using mixed meals with different macronutrients. The investigators address how metabolic flexibility and metabolome change after consuming standardized meals with different macronutrient ratios. Data collection includes clinical and diet information, indirect calorimetry, and capillary blood sampling during fasting and after consumption of standardized meals. Samples are collected weekly for one month. The data will determine the metabolic flexibility and metabolome after consuming standardized meals with different macronutrient ratios.",[568,569,570,571,37],"Fasting","Postprandial Hyperglycemia","Lipid Metabolism Disorders","Glucose Metabolism Disorders",[573,574,575],"metabolic flexibility","postprandial response","mixed meals","2025-03-10",{"date":578,"type":64},"2025-03-17",{"date":580,"type":64},"2024-01-08",{"date":582,"type":21},"2026-12-18",{"name":584,"class":585},"Instituto Nacional de Medicina Genomica","OTHER_GOV",{"id":587,"slug":588,"hasResults":12,"nctId":589,"briefTitle":590,"officialTitle":590,"acronym":4,"eligibilityCriteria":591,"healthyVolunteers":12,"sex":17,"minAge":506,"maxAge":592,"enrollmentInfo":593,"targetDuration":4,"studyType":22,"phases":595,"briefSummary":596,"conditions":597,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":598,"lastUpdatePostDateStruct":599,"startDateStruct":601,"completionDateStruct":603,"leadSponsor":604,"locationsCount":127},"100532734","effect-of-pulsatile-hormone-administration-on-insulin-action-100532734","NCT06216665","Effect of Pulsatile Hormone Administration on Insulin Action","Inclusion Criteria:\n\n* Completion of the Motivate Study (NCT05649176)\n\nExclusion Criteria:\n\n* Non-completion of the end-of-study hyperinsulinemic euglycemic clamp test of the Motivate study","75 Years",{"count":594,"type":21},12,[24],"In humans, insulin is secreted in pulses from the pancreatic beta-cells, and these oscillations help to maintain fasting plasma glucose levels within a narrow normal range. Given the fluctuations in insulin concentrations, oscillations enhance precision of control. The hyperinsulinemic euglycemic clamp test (clamp) involves a continuous infusion of insulin and is the gold standard for measuring insulin sensitivity. In this study, insulin sensitivity measured using the standard clamp will be compared with a clamp in which the same total amount of insulin as the standard clamp is infused every five minutes instead of continuously.",[37],"2025-01-14",{"date":600,"type":64},"2025-01-16",{"date":602,"type":64},"2024-03-04",{"date":325,"type":21},{"name":329,"class":71},{"id":606,"slug":607,"hasResults":12,"nctId":608,"briefTitle":609,"officialTitle":610,"acronym":4,"eligibilityCriteria":611,"healthyVolunteers":106,"sex":17,"minAge":18,"maxAge":612,"enrollmentInfo":613,"targetDuration":4,"studyType":22,"phases":614,"briefSummary":615,"conditions":616,"keywords":623,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":626,"lastUpdatePostDateStruct":627,"startDateStruct":629,"completionDateStruct":631,"leadSponsor":633,"locationsCount":127},"100529981","effect-of-sleep-extension-on-ceramides-in-people-with-overweight-and-obesity-100529981","NCT06180837","Effect of Sleep Extension on Ceramides in People with Overweight and Obesity","Biomarkers of Habitual Short Sleep and Related Cardiometabolic Risk","Inclusion Criteria:\n\n1. Age: 18-45 years old; equal numbers of men and women\n2. Body mass index (BMI): 27.5-34.9 kg\u002Fm2\n3. Sleep Habits: habitual self-reported average total sleep time (TST) \\\u003C6.5 hours per night for prior 6 months\n\nExclusion Criteria:\n\n1. Clinically diagnosed sleep disorder or major psychiatric illness\n2. Evidence of significant organ dysfunction or disease (e.g., heart disease, kidney disease)\n3. Clinically diagnosed diabetes or fasting plasma glucose ≥126 mg\u002FdL or HbA1c ≥6.5%\n4. Use of prescription drugs or substances known to influence sleep or glucose metabolism, or anticoagulant medications.\n5. Cancer that has been in remission less than 5 years\n6. Pregnant\u002Fnursing, experiencing menopause or post-menopausal\n7. Shift-work: current or history of within last year\n8. Weight change: \\>10% of body weight over prior six months\n9. Current enrollment in weight loss or physical activity program like the Diabetes Prevention Program\n10. Currently smoking\n11. Alcohol intake\\>14 drinks per week or \\>3 drinks per day","45 Years",{"count":109,"type":21},[24],"The overall goal is to determine how a sleep extension intervention (increasing time in bed) in individuals who maintain less than 6.5 hours sleep per night affects their plasma ceramides and insulin sensitivity. Participants will undergo a randomized controlled trial, with sleep extension (intervention) and healthy lifestyle (control) groups. The sleep extension is designed to increase participant's time in bed by 2 hours per night. Alternatively, the control group will receive basic health information (e.g., physical activity, goal setting, and nutrition when eating out).",[617,541,37,618,619,620,89,621,622],"Lifestyle Factors","Eating Habit","Sleep Hygiene","Type 2 Diabetes","Sleep Deprivation","Insufficient Sleep Syndrome",[624,625],"sleep","insulin sensitivity","2024-12-18",{"date":628,"type":64},"2024-12-20",{"date":630,"type":64},"2024-02-12",{"date":632,"type":21},"2028-01",{"name":528,"class":71},{"id":635,"slug":636,"hasResults":12,"nctId":637,"briefTitle":638,"officialTitle":639,"acronym":640,"eligibilityCriteria":641,"healthyVolunteers":106,"sex":17,"minAge":18,"maxAge":612,"enrollmentInfo":642,"targetDuration":4,"studyType":22,"phases":643,"briefSummary":644,"conditions":645,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":626,"lastUpdatePostDateStruct":648,"startDateStruct":649,"completionDateStruct":651,"leadSponsor":653,"locationsCount":127},"100511760","circadian-intervention-to-improve-cardiometabolic-health-100511760","NCT05943626","Circadian Intervention to Improve Cardiometabolic Health","Timing of Circadian Synchronizers: the TOCS Study","TOCS","Inclusion Criteria:\n\n1. Age: 18-45 years old; equal numbers of men and women\n2. Body mass index (BMI): 25.0-34.9 kg\u002Fm2,\n3. Sleep Habits: habitual self-reported average total sleep time (TST) \\\u003C6.5 hours per night for prior 6 months\n\nExclusion Criteria:\n\n1. Clinically diagnosed sleep disorder or major psychiatric illness\n2. Evidence of significant organ dysfunction or disease (e.g., diagnosed diabetes, cardiovascular disease, or kidney disease)\n3. Use of prescription drugs or substances known to influence sleep or glucose metabolism\n4. Shift-work: current or history of within last year\n5. Weight change: \\>10% of body weight over prior six months\n6. Experiencing menopause or post-menopausal\n7. Current enrollment in weight loss or physical activity program like the Diabetes Prevention Program\n8. Currently pregnant or planning to become pregnant, or currently lactating.\n9. Currently smoking\n10. Alcohol intake \\>3 drinks per day or \\>14 drinks per week",{"count":509,"type":21},[24],"The overall goal is to examine the efficacy of a circadian intervention in people with overweight and obesity and habitual short sleep duration (HSSD). Participants will undergo a randomized controlled trial, with circadian intervention and control (healthy lifestyle) groups. The circadian intervention is designed to reduce nighttime light exposure and after-dinner snack food intake. Alternatively, the control group will receive basic health information (e.g., physical activity, goal setting, and nutrition when eating out).",[646,620,89,647,617,541,37,618,619],"Cardiometabolic Syndrome","Time Restricted Feeding",{"date":628,"type":64},{"date":650,"type":64},"2023-06-13",{"date":652,"type":21},"2026-03",{"name":528,"class":71},{"id":655,"slug":656,"hasResults":12,"nctId":657,"briefTitle":658,"officialTitle":659,"acronym":4,"eligibilityCriteria":660,"healthyVolunteers":106,"sex":17,"minAge":18,"maxAge":209,"enrollmentInfo":661,"targetDuration":4,"studyType":22,"phases":663,"briefSummary":664,"conditions":665,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":667,"lastUpdatePostDateStruct":668,"startDateStruct":670,"completionDateStruct":672,"leadSponsor":673,"locationsCount":72},"100503281","obesity-insulin-resistance-and-pasc-persistent-sars-cov-2-100503281","NCT05833217","Obesity, Insulin Resistance, and PASC: Persistent SARS-CoV-2","Obesity, Insulin Resistance, and PASC: Persistent SARS-CoV-2 Infection and Inflammation in Human Adipose Tissue","Inclusion Criteria:\n\n* Ages 18 to 80\n* BMI ≥ 25 kg\u002Fm2\n* not currently pregnant\n\nExclusion Criteria:\n\nArm 2 (Adipose Tissue Biopsy) exclusions include\n\n* pregnancy\n* prior liposuction\n* recent change in weight (\\> 2 kg in one month)\n* bleeding disorders\n* anticoagulant use\n\nArm 3 (healthy controls only) exclusions include patients with\n\n* major organ disease\n* diabetes\n* history of liposuction\n* bariatric surgery\n* eating disorders\n* psychiatric disorders\n* pregnancy or lactation\n* recent change in weight (over the past 12 weeks),\n* use of weight loss medication or oral steroids\n* hematocrit \\\u003C 33%\n* fasting glucose \\>= 126 mg\u002FdL\n* blood pressure \\>160\u002F100 mmHg",{"count":662,"type":21},55,[24],"The investigators are studying the pathophysiologic links between obesity, insulin resistance (IR), adipose tissue infection, and post-acute sequelae of COVID-19 (PASC). This study looks at whether adipose (fat) tissue contributes to PASC by driving chronic inflammation or by serving as a reservoir for SARS-CoV-2 persistence. The results will not only determine whether obesity and IR are risk factors for PASC, but will also define fundamental biology that sets the stage for the investigation of novel or existing therapies that target the causal pathways identified.",[666,36,37],"Long COVID","2024-12-02",{"date":669,"type":64},"2024-12-04",{"date":671,"type":64},"2023-06-06",{"date":526,"type":21},{"name":674,"class":71},"Stanford University"]